TY - JOUR
T1 - Transabdominal amnioinfusion for improving fetal outcomes after oligohydramnios secondary to preterm prelabour rupture of membranes before 26 weeks
AU - Van Teeffelen, Stijn
AU - Pajkrt, Eva
AU - Willekes, Christine
AU - Van Kuijk, Sander M.J.
AU - Mol, Ben Willem J.
PY - 2013/8/3
Y1 - 2013/8/3
N2 - Background: Preterm prelabour rupture of membranes (PPROM) before 26 weeks can delay lung development and can cause pulmonary hypoplasia, as a result of oligohydramnios. Restoring the amniotic fluid volume by transabdominal amnioinfusion might prevent abnormal lung development and might have a protective effect for neurological complications, fetal deformities and neonatal sepsis. Objectives: To assess the effectiveness of transabdominal amnioinfusion in improving perinatal outcome in women with oligohydramnios secondary to rupture of fetal membranes before 26 weeks. Search methods: We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (30 April 2013). Selection criteria: All randomised controlled trials comparing transabdominal amnioinfusion with no transabdominal amnioinfusion. Cluster- or quasi-randomised trials were not eligible for inclusion. In cases where only an abstract was available, we attempted to find the full articles. Data collection and analysis: Two review authors assessed trials for inclusion. No eligible trials were identified. Main results: There are no included studies. Authors' conclusions: There is currently no evidence to evaluate the use of transabdominal amnioinfusion in women with oligohydramnios secondary to rupture of fetal membranes before 26 weeks for improving perinatal outcome. Further research examining the effects of this intervention is needed. Two randomised controlled trials are ongoing but final data have not yet been published.
AB - Background: Preterm prelabour rupture of membranes (PPROM) before 26 weeks can delay lung development and can cause pulmonary hypoplasia, as a result of oligohydramnios. Restoring the amniotic fluid volume by transabdominal amnioinfusion might prevent abnormal lung development and might have a protective effect for neurological complications, fetal deformities and neonatal sepsis. Objectives: To assess the effectiveness of transabdominal amnioinfusion in improving perinatal outcome in women with oligohydramnios secondary to rupture of fetal membranes before 26 weeks. Search methods: We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (30 April 2013). Selection criteria: All randomised controlled trials comparing transabdominal amnioinfusion with no transabdominal amnioinfusion. Cluster- or quasi-randomised trials were not eligible for inclusion. In cases where only an abstract was available, we attempted to find the full articles. Data collection and analysis: Two review authors assessed trials for inclusion. No eligible trials were identified. Main results: There are no included studies. Authors' conclusions: There is currently no evidence to evaluate the use of transabdominal amnioinfusion in women with oligohydramnios secondary to rupture of fetal membranes before 26 weeks for improving perinatal outcome. Further research examining the effects of this intervention is needed. Two randomised controlled trials are ongoing but final data have not yet been published.
UR - http://www.scopus.com/inward/record.url?scp=84893489565&partnerID=8YFLogxK
U2 - 10.1002/14651858.CD009952.pub2
DO - 10.1002/14651858.CD009952.pub2
M3 - Review article
C2 - 23913522
AN - SCOPUS:84893489565
VL - 2013
JO - Cochrane Database of Systematic Reviews
JF - Cochrane Database of Systematic Reviews
SN - 1469-493X
IS - 8
M1 - CD009952
ER -